{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:59:55Z","timestamp":1760425195677,"version":"3.40.4"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>A 36-year-old man with known schizophrenia, presented with increasingly bizarre behaviour. The development of catatonia and subsequent neuroleptic malignant syndrome in itself posed numerous therapeutic challenges. However, following resolution of neuroleptic malignant syndrome, the reintroduction of antipsychotics was not tolerated. This case report proposes a novel use for electroconvulsive therapy as a treatment of mental state, following resolution of neuroleptic malignant syndrome, to facilitate successful reintroduction of antipsychotics.<\/jats:p>","DOI":"10.1136\/bcr-2013-009153","type":"journal-article","created":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T12:01:03Z","timestamp":1375099263000},"page":"bcr2013009153","source":"Crossref","is-referenced-by-count":3,"title":["Catatonic schizophrenia: therapeutic challenges and potentially a new role for electroconvulsive therapy?"],"prefix":"10.1136","volume":"2013","author":[{"given":"Deirdre","family":"Philbin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Mulryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"O'Grady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,7,29]]},"reference":[{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.1","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"2013","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00004850-200411000-00007","article-title":"Aripiprazole and neuroleptic malignant syndrome","volume":"2013","author":"Chakraborty","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"issue":"(Suppl 1)","key":"2025042708551749000_2013.jul29_1.bcr2013009153.3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1353-8020(02)00125-6","article-title":"Malignant syndrome in Parkinson's disease: concept and review of the literature","volume":"2013","author":"Mizuno","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.encep.2009.03.009","article-title":"Are catatonia and neuroleptic malignant syndrome related conditions?","volume":"2013","author":"Vesperini","year":"2010","journal-title":"Encephale"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/ajp.156.2.169","article-title":"Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome","volume":"2013","author":"Gurrera","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4088\/JCP.v59n0509a","article-title":"Is risk of neuroleptic malignant syndrome increased in the postpartum period?","volume":"2013","author":"Alexander","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0006-3223(98)00109-7","article-title":"Serum iron in catatonia and neuroleptic malignant syndrome","volume":"2013","author":"Lee","year":"1998","journal-title":"Biol Psychiatry"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.8","first-page":"800","article-title":"Risk factors for neuroleptic malignant syndrome","volume":"2013","author":"Akpaffiong","year":"1992","journal-title":"J Natl Med Assoc"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.9","unstructured":"Benzer T . Neuroleptic malignant syndrome. 2005. http:\/\/www.emedicine.com"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bja\/85.1.129","article-title":"Neuroleptic malignant syndrome","volume":"2013","author":"Adnet","year":"2000","journal-title":"Br J Anaesth"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.11","first-page":"199","article-title":"Neuroleptic malignant syndrome. Case reports","volume":"2013","author":"Berardi","year":"1994","journal-title":"Minerva Psichiatr"},{"key":"2025042708551749000_2013.jul29_1.bcr2013009153.12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/j.1440-1614.1999.00630.x","article-title":"Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases","volume":"2013","author":"Trollor","year":"1999","journal-title":"Aust N Z J Psychiatry"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-009153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T15:55:24Z","timestamp":1745769324000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-009153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,29]]},"references-count":12,"alternative-id":["10.1136\/bcr-2013-009153"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-009153","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2013,7,29]]}}}